XIAP and inflammatory breast carcinoma: In the present study, using cellular models of IBC with high expression of either EGFR or HER2, we demonstrate that XIAP expression modulates IBC cell susceptibility to NK-mediated ADCC when challenged with the anti-EGFR antibody cetuximab or the anti-HER2 antibody trastuzumab, respectively.